ReviewClinical obstetrics and gynecology2017
Ovarian Cancer Prevention in High-risk Women.
Review in Clinical obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Systematic mapping review of guidelines forInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Pooled it
- Endometriosis and autoimmunity.Autoimmunity reviews · 2025Review
- Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Genetic Testing Uptake among Ovarian Cancer Survivors in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study.Cancers · 2024Article
- Knockdown of LIMD2 inhibits the progression of ovarian carcinoma through ERK1/2 pathway.Molecular biology reports · 2023Article
- The Role of Statins in the Prevention of Ovarian and Endometrial Cancers.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.International journal of environmental research and public health · 2022Review
- A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.Acta bio-medica : Atenei Parmensis · 2022Article
- Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.Cancers · 2022Review
- Review
- New approaches in ovarian cancer based on genetics and carcinogenesis hypotheses (Review).Experimental and therapeutic medicine · 2022Review
- Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas.Clinical and experimental vaccine research · 2022Article
- Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.PloS one · 2022Article
- The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells.International journal of molecular sciences · 2021Article
- Nutrition in Gynecological Diseases: Current Perspectives.Nutrients · 2021Review
- Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Association between vitamin D and ovarian cancer development inOncotarget · 2020Article
- Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.Scientific reports · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Ovarian carcinoma is the most lethal malignancy of the female genital tract. Population-based trials in the general population have not demonstrated that screening improves early detection or survival. Therefore, application of prevention strategies is vital to improving outcomes from this disease. Surgical prevention reduces risk and prophylactic risk-reducing salpingo-oophorectomy is the most effective means to prevent ovarian carcinoma in the high-risk patient although the risks do not outweigh the benefits in average risk patients. Other surgical and medical options have unknown or limited efficacy in the high-risk patient. In this review, we define the patient at high risk for ovarian cancer, discuss how to identify these women and weigh their available ovarian cancer prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.